Precision med startup PreciThera nets $36 mln in Series A round
Precision medicine company PreciThera Inc has raised $36 million in a Series A financing. The round, which follows PreciThera's seed funding in May, was backed by Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital. Montréal-based PreciThera is focused on designing biological therapeutics for the treatment of orphan bone diseases. It plans to use the funds raised to develop novel molecules and advance its lead therapeutic candidate through IND and into clinical studies. The company was founded in 2016 by Dr. Philippe Crine, who previously founded Enobia Pharma Corp, and Dr. Susan Schiavi.
27 July 2017•5 mins read
